ProMIS Neurosciences files 8-K, furnishes Nov 12, 2025 press release

Rhea-AI Filing Summary

ProMIS Neurosciences Inc. filed a Form 8-K to furnish its latest financial update. The company reported that a press release detailing its financial condition and results for the three and nine months ended September 30, 2025 has been made available. The release is posted on the company’s website under Investors/Financial Results and is included as Exhibit 99.1.

The filing lists the company’s common shares trading on The Nasdaq Capital Market under the symbol PMN. The press release is dated November 12, 2025 and is incorporated by reference under Item 2.02 (Results of Operations and Financial Condition).

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001374339false00013743392025-11-122025-11-12

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2025

PROMIS NEUROSCIENCES INC.

(Exact name of registrant as specified in its charter)

​

Canada		001-41429		98-0647155
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

​

​

Suite 200, 1920 Yonge Street, Toronto, Ontario				M4S 3E2
(Address of principal executive offices)				(Zip Code)

​

Registrant’s telephone number, including area code: (416) 847-6898

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common Shares, no par value per share	​	PMN		The Nasdaq Capital Market

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

Item 2.02 Results of Operations and Financial Condition

On May 12, 2025, ProMIS Neurosciences Inc. (the "Company") issued a press release, which is available on its website (www.promisneurosciences.com under “Investors/Financial Results”), reporting its financial condition and financial results as of and for the three months and nine months ended September 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this report and is incorporated by reference into this Item 2.02.

​

​

​

​

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

​	​	​
Exhibit No.		Description
99.1	​	Press Release, dated November 12, 2025
104	​	Cover Page Interactive Data File (embedded within the Inline XBRL document)

​

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​	​	​
​	PROMIS NEUROSCIENCES INC.
​	​	​
Date: November 12, 2025	By:	/s/ Neil Warma
​	​	Name: Neil Warma
​	​	Title: Chief Executive Officer

​

​

​

FAQ

What did ProMIS Neurosciences (PMN) announce in this 8-K?

It furnished a press release reporting its financial condition and results for the three and nine months ended September 30, 2025.

Where can I find the ProMIS (PMN) financial press release?

It is available on the company’s website under Investors/Financial Results and attached as Exhibit 99.1.

What period does the ProMIS (PMN) update cover?

The press release covers the three and nine months ended September 30, 2025.

What is the date of the ProMIS (PMN) press release?

November 12, 2025.

Which exhibit contains the ProMIS (PMN) press release?

Exhibit 99.1.

On which exchange does ProMIS (PMN) trade and what is the symbol?

The Nasdaq Capital Market, ticker PMN.